908 Devices’ (MASS) Sell (E+) Rating Reaffirmed at Weiss Ratings

908 Devices (NASDAQ:MASS)‘s stock had its “sell (e+)” rating reiterated by stock analysts at Weiss Ratings in a research report issued to clients and investors on Saturday,Weiss Ratings reports.

Several other research analysts also recently weighed in on the stock. Leerink Partners restated a “market perform” rating and set a $4.00 price target (down previously from $12.00) on shares of 908 Devices in a research report on Wednesday, November 13th. Stephens restated an “overweight” rating and set a $6.00 price target on shares of 908 Devices in a research report on Wednesday, January 15th. Leerink Partnrs downgraded shares of 908 Devices from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 13th. Finally, Stifel Nicolaus reduced their price target on shares of 908 Devices from $17.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Two analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $5.33.

908 Devices Stock Down 8.4 %

MASS stock opened at $2.29 on Friday. The company’s 50-day simple moving average is $2.36 and its 200-day simple moving average is $3.29. 908 Devices has a 52-week low of $1.81 and a 52-week high of $7.91. The firm has a market cap of $79.74 million, a P/E ratio of -1.29 and a beta of 0.98.

Institutional Trading of 908 Devices

Hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new stake in 908 Devices in the 3rd quarter valued at about $36,000. B. Riley Wealth Advisors Inc. acquired a new stake in 908 Devices in the 3rd quarter valued at about $45,000. Drive Wealth Management LLC purchased a new stake in shares of 908 Devices in the 3rd quarter valued at approximately $50,000. Townsquare Capital LLC purchased a new stake in shares of 908 Devices in the 3rd quarter valued at approximately $50,000. Finally, Concurrent Investment Advisors LLC purchased a new stake in shares of 908 Devices in the 4th quarter valued at approximately $52,000. Institutional investors and hedge funds own 88.06% of the company’s stock.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.